GlassScriptPhysician profile
Jayanthi Alagarsamy
NPI 1710976089
$3,741.73
in general payments reported to CMS, 2019-2025
24 companies · $1,243 in 2025
The $1,243 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $359 · 2020: $430 · 2021: $543 · 2022: $471 · 2023: $15.67 · 2024: $681 · 2025: $1,243.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,940.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,939.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $995.37 | 2019-2025 | Airsupra, Lokelma, Farxiga |
| Vanda Pharmaceuticals INC. | $440.47 | 2024-2025 | Fanapt |
| Novo Nordisk INC | $360.24 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $218.55 | 2020-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $170.11 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $154.17 | 2021 | |
| Scilex Pharmaceuticals INC. | $146.07 | 2019 | |
| Phathom Pharmaceuticals, INC. | $140.55 | 2025 | Voquezna |
| Astellas Pharma US INC | $133.92 | 2025 | Veozah |
| Xeris Pharmaceuticals, INC. | $125.57 | 2025 | Gvoke Hypopen |
| Allergan, INC. | $123.08 | 2020 | |
| Pfizer INC. | $115.70 | 2019-2025 | |
| Amgen INC. | $95.03 | 2021 | |
| Glaxosmithkline, LLC. | $93.16 | 2020-2025 | Arexvy |
| Nestle Healthcare Nutrition INC. | $87.40 | 2020-2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $72.71 | 2019-2024 | Taltz, Zepbound, Mounjaro |
| Exact Sciences Corporation | $50.44 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $47.84 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $39.00 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $36.71 | 2025 | Eliquis, Camzyos |
| Alexion Pharmaceuticals, INC. | $29.73 | 2025 | Strensiq |
| Janssen Pharmaceuticals, INC | $27.19 | 2019 | |
| Avanir Pharmaceuticals, INC. | $20.82 | 2019 | |
| Ucb, INC. | $17.90 | 2025 | Bimzelx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jayanthi Alagarsamy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.